ANIXA BIOSCIENCES, INC. Proceeds from Customers
ANIXA BIOSCIENCES, INC. (ANIX) reported Proceeds from Customers of $2.13 thousand for the 9-month period ending 2013-07-31, per its 10-Q/A filed 2013-09-20.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromCustomers · last filed 2013-09-20
- ANIXA BIOSCIENCES, INC. proceeds from customers for the quarter ending 2013-07-31 was $0.00, a 100.00% decline year-over-year.
- ANIXA BIOSCIENCES, INC. proceeds from customers for the quarter ending 2013-04-30 was $0.00, a 100.00% decline year-over-year.
- ANIXA BIOSCIENCES, INC. proceeds from customers for the quarter ending 2013-01-31 was $2.13K, a 15.64% decline year-over-year.
- ANIXA BIOSCIENCES, INC. proceeds from customers for the quarter ending 2012-10-31 was $1.75K, a 212.50% increase year-over-year.
- ANIXA BIOSCIENCES, INC. proceeds from customers for fiscal 2012 was $7.08K, a 94.58% decline from fiscal 2011.
- ANIXA BIOSCIENCES, INC. proceeds from customers for fiscal 2011 was $130.52K, a 2.86% increase from fiscal 2010.
- ANIXA BIOSCIENCES, INC. proceeds from customers for fiscal 2010 was $126.89K.
| Period end | Proceeds from Customers 3 month | Proceeds from Customers 6 month | Proceeds from Customers 9 month | Proceeds from Customers 12 month |
|---|---|---|---|---|
| 2013-07-31 | $0.00 derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2013-09-20 | $0.00 derived: sum of 2 quarters · filed 2013-09-20 | $2.13K 10-Q/A · filed 2013-09-20 | $3.88K derived: sum of 4 quarters · filed 2013-09-20 |
| 2013-04-30 | $0.00 derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2013-06-19 | $2.13K 10-Q/A · filed 2013-06-19 | $3.88K derived: sum of 3 quarters · filed 2013-06-19 | $5.28K derived: sum of 4 quarters · filed 2013-09-20 |
| 2013-01-31 | $2.13K 10-Q/A · filed 2013-03-25 | $3.88K derived: sum of 2 quarters · filed 2013-03-25 | $5.28K derived: sum of 3 quarters · filed 2013-09-20 | $6.68K derived: sum of 4 quarters · filed 2013-09-20 |
| 2012-10-31 | $1.75K derived: 10-K 12 month − 10-Q/A 9 month · filed 2013-01-29 | $3.15K derived: sum of 2 quarters · filed 2013-09-20 | $4.55K derived: sum of 3 quarters · filed 2013-09-20 | $7.08K 10-K · filed 2013-01-29 |
| 2012-07-31 | $1.40K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2013-09-20 | $2.80K derived: sum of 2 quarters · filed 2013-09-20 | $5.33K 10-Q/A · filed 2013-09-20 | $5.88K derived: sum of 4 quarters · filed 2013-09-20 |
| 2012-04-30 | $1.40K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2013-06-19 | $3.92K 10-Q/A · filed 2013-06-19 | $4.49K derived: sum of 3 quarters · filed 2013-06-19 | $32.27K derived: sum of 4 quarters · filed 2013-06-19 |
| 2012-01-31 | $2.52K 10-Q/A · filed 2013-03-25 | $3.08K derived: sum of 2 quarters · filed 2013-03-25 | $30.88K derived: sum of 3 quarters · filed 2013-03-25 | $119.19K derived: sum of 4 quarters · filed 2013-03-25 |
| 2011-10-31 | $560.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-01-29 | $28.35K derived: sum of 2 quarters · filed 2013-01-29 | $116.67K derived: sum of 3 quarters · filed 2013-01-29 | $130.52K 10-K · filed 2013-01-29 |
| 2011-07-31 | $27.79K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-09-14 | $116.11K derived: sum of 2 quarters · filed 2012-09-14 | $129.96K 10-Q · filed 2012-09-14 | $141.21K derived: sum of 4 quarters · filed 2012-09-14 |
| 2011-04-30 | $88.31K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-06-14 | $102.17K 10-Q · filed 2012-06-14 | $113.42K derived: sum of 3 quarters · filed 2012-06-14 | |
| 2011-01-31 | $13.86K 10-Q · filed 2012-03-16 | $25.11K derived: sum of 2 quarters · filed 2012-03-16 | ||
| 2010-10-31 | $11.25K derived: 10-K 12 month − 10-Q/A 9 month · filed 2012-01-30 | $126.89K 10-K · filed 2012-01-30 | ||
| 2010-07-31 | $115.64K 10-Q/A · filed 2011-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 |